查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1468272

2024-2032 年按疾病、应用和地区分類的中枢神经系统治疗市场报告

Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球中枢神经系统（CNS）治疗市场规模达1,401亿美元。大众中神经和精神疾病的盛行率不断上升、远距医疗和远距医疗服务的兴起以及贸易协定和伙伴关係的增加是推动市场成长的关键因素。

中枢神经系统 (CNS) 治疗重点是治疗和管理影响大脑和脊髓（构成中枢神经系统）的疾病。这些疾病的范围从神经退化性疾病（如阿兹海默症和帕金森氏症）到精神疾病（如忧郁症和焦虑症）。它们还涵盖急性病症，包括创伤性脑损伤和中风。治疗领域广阔，包括各种方法，例如药物介入、外科手术和包括基因治疗在内的新模式。药物可以包括抗忧郁药、抗精神病药或专门针对神经通路设计的药物。在神经科学和生物技术进步的推动下，该领域的研究不断发展。

中枢神经系统（CNS）治疗产业的主要市场驱动力之一是全球神经系统和精神疾病盛行率的上升。由于人口老化、生活方式的改变和环境压力等因素，阿兹海默症、帕金森氏症、忧郁症和焦虑症等疾病变得越来越普遍。随着需要中枢神经系统治疗的患者数量不断增加，市场潜力不断扩大，使其成为投资和创新的有吸引力的领域。同时，远距医疗和远距医疗服务的兴起被证明是市场成长的重要动力。 COVID-19 大流行加速了远距医疗保健的采用，而且这种趋势可能会持续下去。远距医疗服务使患者可以更方便地寻求医疗建议并获得中枢神经系统疾病的处方，而无需亲自预约。这种增加的可近性对于偏远地区的人们特别有利，扩大了中枢神经系统治疗的患者基础。此外，监管机构越来越愿意加快创新中枢神经系统治疗药物的审批，特别是那些解决未满足的医疗需求的药物。因此，它正在为市场做出贡献。此外，全球化往往会促进贸易协定和伙伴关係，为中枢神经系统治疗产品提供更精简的分销网络，并创造积极的市场前景。

中枢神经系统 (CNS) 治疗市场趋势/驱动因素：

药物发现的技术进步

科技的快速进步是中枢神经系统治疗产业的关键驱动力。人工智慧 (AI)、机器学习和巨量资料分析等技术正在增强传统的药物发现方法。这些技术有助于更快地识别潜在的候选药物，从而加快药物开发的进程。高通量筛选方法也变得更加复杂，使研究人员能够在更短的时间内评估数千种化合物。生物资讯学工具和计算模型越来越多地用于在分子层面上理解疾病途径，有助于标靶治疗的开发。这些技术进步显着减少了将新的中枢神经系统治疗药物推向市场的时间和成本，为行业成长提供了强劲动力。

公众意识和医疗基础设施

近年来，大众对心理健康和神经系统疾病的认识显着提高。这种认识的提高导致了早期诊断和治疗，从而推动了对中枢神经系统治疗的需求。此外，政府和医疗机构越来越认识到心理健康的重要性，从而改善医疗基础设施和政策，促进中枢神经系统药物的开发和分销。在许多已开发国家，保险范围已扩大到包括神经和精神疾病的治疗，使更广泛的人群更容易获得治疗。神经科诊所和復健中心等专业医疗机构的兴起，为中枢神经系统治疗增加了另一层市场潜力。随着医疗保健基础设施不断改善，有效和创新的中枢神经系统治疗方法的市场也在不断完善。

不断增加的研发投资

研究与开发 (R&D) 是中枢神经系统治疗产业的支柱，而该领域不断增长的投资是重要的市场驱动力。此外，製药公司通常与学术机构和研究组织合作，投入大量资源进行研发活动。这种伙伴关係促进了专业知识和财政资源的共享，从而加快了开发进程。此外，政府补助、创投和公私合作伙伴关係在支持研发工作方面也发挥越来越大的作用。这种协作环境带来了突破性的发现，包括治疗中枢神经系统疾病的标靶疗法和个人化医疗方法。高投资回报的承诺，加上对有效治疗的持续需求，确保研发资金仍然是中枢神经系统治疗产业成长的强大驱动力。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球中枢神经系统 (CNS) 治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疾病分类

  • 神经退化性疾病
    • 市场走向
    • 关键环节
      • 阿兹海默氏症
      • 帕金森氏症
      • 多发性硬化症
      • 亨丁顿舞蹈症
      • 肌萎缩侧索硬化症
      • 其他的
    • 市场预测
  • 神经血管疾病
    • 市场走向
    • 市场预测
  • 中枢神经系统创伤
    • 市场走向
    • 市场预测
  • 精神健康
    • 市场走向
    • 关键环节
      • 焦虑症
      • 癫痫
      • 情绪障碍
      • 精神障碍
      • 其他的
    • 市场预测
  • 传染性疾病
    • 市场走向
    • 市场预测
  • 中枢神经系统癌症
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按应用

  • 医院
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 居家护理
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca plc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG (Roche Holding)
    • H. Lundbeck A/S
    • Merck & Co. Inc.
    • Neurocrine Biosciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A6114

The global central nervous system (CNS) therapeutics market size reached US$ 140.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 239.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032. The growing prevalence of neurological and psychiatric disorders among the masses, the rise in telehealth and telemedicine services, and the increase in trade agreements and partnerships are among the key factors driving the market growth.

Central nervous system (CNS) therapeutics focus on the treatment and management of disorders affecting the brain and spinal cord, which make up the central nervous system. These disorders can range from neurodegenerative diseases, such as Alzheimer's and Parkinson's to psychiatric conditions such as depression and anxiety. They also cover acute conditions, including traumatic brain injuries and strokes. The treatment landscape is vast and includes various approaches, such as pharmacological interventions, surgical procedures, and newer modalities, including gene therapy. Medications can consist of antidepressants, antipsychotics, or drugs specifically designed to target neural pathways. Research in this field is continually evolving, driven by advancements in neuroscience and biotechnology.

One of the primary market drivers for the central nervous system (CNS) therapeutics industry is the rising prevalence of neurological and psychiatric disorders globally. Conditions such as Alzheimer's, Parkinson's, depression, and anxiety are becoming increasingly common due to factors, such as an aging population, lifestyle changes, and environmental stressors. With an increasing number of patients requiring CNS therapeutics, the market potential continues to expand, making it an attractive area for investment and innovation. Along with this, the rise in telehealth and telemedicine services is proving to be a significant driver in the market growth. The COVID-19 pandemic has accelerated the adoption of remote healthcare, and this trend is likely to continue. Telehealth services make it more convenient for patients to seek medical advice and obtain prescriptions for CNS disorders without the need for physical appointments. This increased accessibility is particularly beneficial for those in remote areas, broadening the patient base for CNS therapeutics. In addition, regulatory agencies are showing an increased willingness to fast-track the approval of innovative CNS therapeutic drugs, particularly those addressing unmet medical needs. Therefore, it is contributing to the market. Moreover, trade agreements and partnerships are often facilitated by globalization, providing a more streamlined distribution network for CNS therapeutic products, and creating a positive market outlook.

Central Nervous System (CNS) Therapeutics Market Trends/Drivers:

Technological Advancements in Drug Discovery

The rapid advancements in technology have been a crucial driver for the CNS therapeutics industry. Traditional methods of drug discovery are being augmented by technologies such as artificial intelligence (AI), machine learning, and big data analytics. These technologies help in quicker identification of potential drug candidates, thereby speeding up the process of drug development. High-throughput screening methods have also become more sophisticated, allowing researchers to evaluate thousands of compounds in a shorter time frame. Bioinformatics tools and computational models are increasingly used for understanding disease pathways at the molecular level, aiding in the development of targeted therapies. These technological strides have significantly reduced the time and cost associated with bringing a new CNS therapeutic drug to market, providing a robust impetus for industry growth.

Public Awareness and Healthcare Infrastructure

Public awareness about mental health and neurological disorders has grown significantly in recent years. This increased awareness has led to early diagnosis and treatment, subsequently driving the demand for CNS therapeutics. Furthermore, governments and healthcare organizations are increasingly recognizing the importance of mental health, leading to better healthcare infrastructure and policies that facilitate the development and distribution of CNS drugs. In many developed countries, insurance coverage has expanded to include treatments for neurological and psychiatric disorders, making therapies more accessible to a broader population. The rise in specialized healthcare facilities, such as neurology clinics and rehabilitation centers, adds another layer of market potential for CNS therapeutics. As healthcare infrastructure continues to improve, so does the market for effective and innovative CNS treatments.

Growing Investment in Research and Development

Research and development (R&D) form the backbone of the CNS therapeutics industry, and growing investment in this area serves as a substantial market driver. Additionally, pharmaceutical companies are dedicating significant resources to R&D activities, often in collaboration with academic institutions and research organizations. Such partnerships facilitate the sharing of expertise and financial resources, thereby expediting the development process. In addition, government grants, venture capital funding, and public-private partnerships are also playing an increasing role in supporting R&D efforts. This collaborative environment has led to groundbreaking discoveries, including targeted therapies and personalized medicine approaches for treating CNS disorders. The promise of high returns on investment, coupled with the ever-present demand for effective treatments, ensures that R&D funding remains a strong driver for the growth of the CNS Therapeutics industry.

Central Nervous System (CNS) Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the central nervous system (CNS) therapeutics market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on disease and application.

Breakup by Disease:

Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Huntington's Disease

Amyotrophic Lateral Sclerosis

Others

Neurovascular Diseases

CNS Trauma

Mental Health

Anxiety Disorders

Epilepsy

Mood Disorders

Psychotic Disorders

Others

Infectious Diseases

CNS Cancer

Others

Neurodegenerative Diseases represent the largest market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, and others), neurovascular diseases, CNS trauma, mental health (anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others), infectious diseases, CNS cancer, and others. According to the report, neurodegenerative diseases accounted for the largest market share.

The rising incidence of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Multiple Sclerosis is a significant market driver in the central nervous system (CNS) Therapeutics industry. As the global population ages, the prevalence of these conditions is expected to escalate, increasing the demand for effective treatments. Along with this, the socioeconomic burden these diseases place on healthcare systems and families is pushing both public and private sectors to invest heavily in research and development. Technological advancements, such as biomarker identification and gene editing, are accelerating the pace of drug discovery for neurodegenerative conditions, attracting further investment. Additionally, government initiatives and regulatory support, mainly fast-track approvals and grants, provide an impetus for pharmaceutical companies to develop innovative solutions. In addition, the growing public awareness and educational campaigns around neurodegenerative diseases are also contributing to market growth by encouraging early diagnosis and treatment. All these factors collectively create a conducive environment for the expansion of the CNS Therapeutics market in the domain of neurodegenerative diseases.

Breakup by Application:

Hospital

Clinic

Homecare

Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes hospital, clinic, homecare, and others.

The role of hospitals as a primary point of care for acute and chronic neurological conditions is a significant market driver in the central nervous system (CNS) therapeutics industry. Hospitals are often equipped with advanced diagnostic tools and treatment facilities, making them essential for managing complex CNS disorders. As cases of traumatic brain injuries, strokes, and emergency psychiatric episodes continue to rise, the need for specialized CNS therapeutics within hospital settings becomes increasingly crucial. The demand is further fueled by the growing number of specialized neurology departments and centers of excellence in hospitals, which require a consistent supply of CNS medications and treatments. Additionally, hospitals are key sites for clinical trials, accelerating the adoption of innovative CNS therapies.

On the contrary, the rising trend towards homecare for managing chronic and post-acute conditions is significantly influencing the Central Nervous System (CNS) therapeutics industry. As technological advancements make remote monitoring and telehealth more viable, many patients prefer receiving care in the comfort of their homes. Homecare is especially relevant for the elderly population and patients with neurodegenerative disorders who may find frequent hospital visits cumbersome. In addition, the availability of easy-to-administer medications and therapies suitable for home use is driving demand in this segment. Moreover, healthcare models are shifting towards more patient-centric approaches, further encouraging the adoption of homecare solutions. These trends not only broaden the consumer base but also open new channels for the distribution of CNS therapeutics, boosting overall market growth.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest central nervous system (CNS) therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest market segment.

The central nervous system (CNS) therapeutics industry in North America is driven by the high prevalence of CNS-related disorders, including mental health conditions, neurodegenerative diseases, and acute neurological issues. According to the Centers for Disease Control and Prevention (CDC), one in five American adults experiences mental illness each year. Furthermore, an aging population in the region significantly contributes to the increased incidence of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's.

In addition, technological innovation is another significant driver, with North America often leading in the development of advanced treatments, including gene therapies and neural implants. The region also benefits from strong regulatory support, with agencies providing fast-track approvals for innovative CNS drugs. Moreover, robust healthcare infrastructure, including advanced hospitals and a growing focus on telehealth services, facilitates easier access to treatments. Furthermore, substantial investment in research and development, both from public and private sectors, furthers innovation and the speed-to-market for new CNS therapies, collectively making North America a dynamic market for CNS therapeutics.

Competitive Landscape:

The key players are allocating significant resources to advance their understanding of CNS disorders, uncover novel treatment approaches, and develop new therapeutic agents. This involves conducting clinical trials, and preclinical studies, and leveraging cutting-edge technologies to identify potential drug candidates. Along with this, brands are leveraging advanced techniques, such as high-throughput screening, molecular modeling, and genetics to discover compounds with the potential to modulate CNS-related targets. These efforts aim to identify effective drug candidates that can address specific neurological conditions. In addition, the growing focus on personalized medicine within the CNS therapeutics field is positively influencing the market. Apart from this, companies are particularly focused on neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Research efforts are aimed at unraveling the underlying mechanisms of these diseases and developing disease-modifying treatments, which act as another growth-inducing factor. Furthermore, the escalating number of collaborations with research institutions, academia, and other industry players to develop new therapeutic approaches is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc

Biogen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG (Roche Holding)

H. Lundbeck A/S

Merck & Co. Inc.

Neurocrine Biosciences Inc.

Novartis AG

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Recent Developments:

In May 2023, AstraZeneca plc gained authorization from the Japanese Ministry of Health, Labour, and Welfare (MHLW) to use Ultomiris (ravulizumab) to stop relapses in patients with neuromyelitis optica spectrum disease (NMOSD), including neuromyelitis optica.

In January 2023, Biogen Inc. and Alcyone Therapeutics (Alcyone) engaged in a licence and cooperation agreement to create the ThecaFlex DRxTM System from Alcyone, an implanted medical device designed for subcutaneous antisense oligonucleotide (ASO) therapy administration into the intrathecal space.

In January 2023, Capsida Biotherapeutics Inc. established a multi-year strategic partnership to develop game-changing genetic treatments for critical illnesses with Prevail Therapeutics ("Prevail"), a fully owned subsidiary of Eli Lilly and Company ("Lilly").

Key Questions Answered in This Report

  • 1. What was the size of the global Central Nervous System (CNS) therapeutics market in 2023?
  • 2. What is the expected growth rate of the global Central Nervous System (CNS) therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global Central Nervous System (CNS) therapeutics market?
  • 4. What has been the impact of COVID-19 on the global Central Nervous System (CNS) therapeutics market?
  • 5. What is the breakup of the global Central Nervous System (CNS) therapeutics market based on the disease?
  • 6. What are the key regions in the global Central Nervous System (CNS) therapeutics market?
  • 7. Who are the key players/companies in the global Central Nervous System (CNS) therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Central Nervous System (CNS) Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease

  • 6.1 Neurodegenerative Diseases
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alzheimer's Disease
      • 6.1.2.2 Parkinson's Disease
      • 6.1.2.3 Multiple Sclerosis
      • 6.1.2.4 Huntington's Disease
      • 6.1.2.5 Amyotrophic Lateral Sclerosis
      • 6.1.2.6 Others
    • 6.1.3 Market Forecast
  • 6.2 Neurovascular Diseases
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 CNS Trauma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mental Health
    • 6.4.1 Market Trends
    • 6.4.2 Key Segments
      • 6.4.2.1 Anxiety Disorders
      • 6.4.2.2 Epilepsy
      • 6.4.2.3 Mood Disorders
      • 6.4.2.4 Psychotic Disorders
      • 6.4.2.5 Others
    • 6.4.3 Market Forecast
  • 6.5 Infectious Diseases
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 CNS Cancer
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hospital
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinic
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Homecare
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biogen Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Eli Lilly and Company
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 F. Hoffmann-La Roche AG (Roche Holding)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 SWOT Analysis
    • 13.3.5 H. Lundbeck A/S
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Merck & Co. Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Neurocrine Biosciences Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sanofi S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Takeda Pharmaceutical Company Limited
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Teva Pharmaceutical Industries Ltd.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Central Nervous System Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Central Nervous System Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Central Nervous System Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Central Nervous System Therapeutics Market: Breakup by Disease (in %), 2023
  • Figure 5: Global: Central Nervous System Therapeutics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Central Nervous System Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Central Nervous System Therapeutics (CNS Trauma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Central Nervous System Therapeutics (CNS Trauma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Central Nervous System Therapeutics (Mental Health) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Central Nervous System Therapeutics (Mental Health) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Central Nervous System Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Central Nervous System Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Central Nervous System Therapeutics (CNS Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Central Nervous System Therapeutics (CNS Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Central Nervous System Therapeutics (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Central Nervous System Therapeutics (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Central Nervous System Therapeutics (Hospital) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Central Nervous System Therapeutics (Hospital) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Central Nervous System Therapeutics (Clinic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Central Nervous System Therapeutics (Clinic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Central Nervous System Therapeutics (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Central Nervous System Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Central Nervous System Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Central Nervous System Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Central Nervous System Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 77: Middle East and Africa: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Global: Central Nervous System Therapeutics Industry: SWOT Analysis
  • Figure 79: Global: Central Nervous System Therapeutics Industry: Value Chain Analysis
  • Figure 80: Global: Central Nervous System Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Central Nervous System Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 3: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Central Nervous System Therapeutics Market: Competitive Structure
  • Table 6: Global: Central Nervous System Therapeutics Market: Key Players